Investor Relations

We are Anchiano Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer in areas of unmet need.

Our initial program is the genetic therapy for early stage bladder cancer. Inodiftagene visteplasmid (BC-819), our most advanced investigational agent, is under development as a treatment for non-muscle-invasive bladder cancer (NMIBC).

We are located in Cambridge, MA, and in Jerusalem, and are publicly traded on the Tel Aviv Stock Exchange.

Scientific and Medical

Focus on discovering and developing therapies for patients with cancer in areas of unmet need

Initial program: genetic therapy for early stage bladder cancer

Utilizes technology licensed from Hebrew University


Founded in 2004; based in Cambridge and Jerusalem

New CEO (former Harvard faculty; Ariad chief medical officer) based in Cambridge, building U.S. team and infrastructure


$45 million (end Q3 2018)
Approximate market capitalization

Publicly traded in Israel (TASE:ANCN)

15.6 million
outstanding shares

22.5 million
fully diluted

$11 million (end Q3 2018)
cash, no debt


Anchiano Therapeutics Announces Filing of F-1 Registration Statement for U.S. Initial Public Offering (January 7, 2019)
Anchiano Therapeutics Announces Initiation of Its Pivotal Codex Study of Inodiftagene Vixteplasmid in Patients with Non-Muscle-Invasive Bladder Cancer (November 26, 2018)
Anchiano Therapeutics Announces Appointment of Dr. David Kerstein as New Chief Medical Officer (November 26, 2018)
Anchiano Therapeutics Appoints Dr. Stephen Hoffman and Robert Connelly to its Board of Directors (November 12, 2018)
Anchiano Therapeutics Announces Confidential Submission of Draft Registration Statement for U.S. Initial Public Offering (October 31, 2018)
Anchiano Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference (September 5, 2018)
Anchiano Therapeutics Appoints Efrat Makov to Board of Directors (August 30, 2018)
BioCanCell Announces Company Name Change to Anchiano Therapeutics (August 27, 2018)
BioCanCell Announces Second Quarter 2018 Financial and Operational Results (August 22, 2018)
BioCanCell Announces Completion of $23 Million PIPE Financing (July 3, 2018)
BioCanCell Reports First Quarter 2018 Financial and Operational Results and Provides Corporate Update (May 15, 2018)
Notice Of The Convening Of An Annual And Extraordinary General Meeting Of The Company’s Shareholders (April 26, 2018)
BioCanCell Announces $23 Million PIPE Financing (April 23, 2018)
BioCanCell Announces Two New Key Hires in Clinical Development and Clinical Operations (March 7, 2018)
BioCanCell Presents Final Data from Its Phase 2 Study of BC-819 for Early Stage Bladder Cancer (February 9, 2018)


Ashley Robinson, LifeSci Advisors


20th Annual Global Investment Conference 


Corporate Presentation